Development of Proneurogenic, Neuroprotective Small Molecules
Citations Over TimeTop 10% of 2011 papers
Abstract
Degeneration of the hippocampus is associated with Alzheimer's disease and occurs very early in the progression of the disease. Current options for treating the cognitive symptoms associated with Alzheimer's are inadequate, giving urgency to the search for novel therapeutic strategies. Pharmacologic agents that safely enhance hippocampal neurogenesis may provide new therapeutic approaches. We discovered the first synthetic molecule, named P7C3, which protects newborn neurons from apoptotic cell death, and thus promotes neurogenesis in mice and rats in the subgranular zone of the hippocampal dentate gyrus, the site of normal neurogenesis in adult mammals. We describe the results of a medicinal chemistry campaign to optimize the potency, toxicity profile, and stability of P7C3. Systematic variation of nearly every position of the lead compound revealed elements conducive toward increases in activity and regions subject to modification. We have discovered compounds that are orally available, nontoxic, stable in mice, rats, and cell culture, and capable of penetrating the blood-brain barrier. The most potent compounds are active at nanomolar concentrations. Finally, we have identified derivatives that may facilitate mode-of-action studies through affinity chromatography or photo-cross-linking.
Related Papers
- → Intracerebroventricular infusion of insulin-like growth factor-I ameliorates the age-related decline in hippocampal neurogenesis(2001)428 cited
- → Impact of age and caloric restriction on neurogenesis in the dentate gyrus of C57BL/6 mice(2003)265 cited
- → Jagged1 is necessary for postnatal and adult neurogenesis in the dentate gyrus(2014)48 cited
- → Differential neurogenesis in the adult rat dentate gyrus: an identifiable zone that consistently lacks neurogenesis(2007)8 cited
- → 190. Neurogenesis Inhibits Stress-Responsive Cells in the Ventral Dentate Gyrus(2018)1 cited